The only available drug is the MEK inhibitor selumetinib, which was approved by the FDA for use in a subset of inoperable pediatric plexiform neurofibromas (PNs) in April 2020 [10]. Here, MAP2K7 is linked to paraneoplastic neurologic syndrome.